Product Information
CICLOPIROX 0.77% TOPICAL SUSP is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.7500 per ML under NDC 45802040049. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Dec 15, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Ciclopirox Olamine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
7.7 mg/100mL
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802040049
Classification
Generic
Dosage Form
SUSPENSION
Route
TOPICAL
Effective Date
8/19/2026
Active Ingredients
CICLOPIROX OLAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA077676FDA Approved
12/15/2006
TE Code
AB
On Market Since
12/29/2006
Pharmacological Classes
Price Statistics
The NADAC for CICLOPIROX 0.77% TOPICAL SUSP has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 58.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7500 per ML |
|---|---|
| All-time high | $1.6970 (Sep 14, 2016) |
| All-time low | $0.3262 (Apr 22, 2015) |
| 52-week high | $0.7797 |
| 52-week low | $0.5857 |
| Median price | $0.8371 |
| Average price | $0.8307 |
| Largest weekly change | +130.8% (May 18, 2016) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CICLOPIROX 0.77% TOPICAL SUSP?
The current National Average Drug Acquisition Cost (NADAC) for CICLOPIROX 0.77% TOPICAL SUSP, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.7500 per ML (NDC 45802040049), effective Aug 19, 2026.
How has the price of CICLOPIROX 0.77% TOPICAL SUSP changed over time?
Over the history we have for it, the NADAC for CICLOPIROX 0.77% TOPICAL SUSP has risen 58.9%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CICLOPIROX 0.77% TOPICAL SUSP?
Since Nov 28, 2013, the NADAC for CICLOPIROX 0.77% TOPICAL SUSP has ranged from a low of $0.3262 (Apr 22, 2015) to a high of $1.6970 (Sep 14, 2016), with a median of $0.8371 per ML.
Are there cheaper alternatives to CICLOPIROX 0.77% TOPICAL SUSP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CICLOPIROX 0.77% TOPICAL SUSP, is $0.7331 per ML — about 2% below CICLOPIROX 0.77% TOPICAL SUSP.
Who manufactures CICLOPIROX 0.77% TOPICAL SUSP?
CICLOPIROX 0.77% TOPICAL SUSP (NDC 45802040049) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.